Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
No Data Available.
Synonyms :
bisacodyl
Class :
Laxative and stimulant
5 - 15
mg
Orally
once a day
For complete emptying 30 mg orally once a day
Age: 6-12 years
5 mg or 0.3 mg/kg orally at bedtime
Age: >12 years
5-15 mg orally at bedtime
it may reduce the therapeutic effect of bisacodyl
it may reduce the therapeutic effect of bisacodyl
it may reduce the therapeutic effect of bisacodyl
it may reduce the therapeutic effect of bisacodyl
it may reduce the therapeutic effect of bisacodyl
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
sodium picosulfate, citric acid, and magnesium oxide
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
bisacodyl: they may decrease the therapeutic effect of antacids
bisacodyl: they may decrease the therapeutic effect of antacids
bisacodyl: they may decrease the therapeutic effect of antacids
bisacodyl: they may decrease the therapeutic effect of antacids
bisacodyl: they may decrease the therapeutic effect of antacids
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
it may increase the risk of adverse effects of sodium sulfate
may decrease the therapeutic effect of Antacids
polyethylene glycol and electrolytesÂ
May enhance the adverse/toxic effect of polyethylene Glycol-electrolyte Solution.
may enhance the pharmacodynamic synergistic effect when combined
it may increase the risk of adverse effects of sodium sulfate
It may enhance the risk of adverse reactions when combined with Laxatives
It may enhance the risk of adverse effects when combined with Prolactine inhibitors
when used with ipratropium, bisacodyl's therapeutic efficacy may be compromised
bisacodyl: it may decrease the therapeutic efficacy of caroverine
bisacodyl's therapeutic efficacy may be reduced when used in combination with almasilate
sodium picosulfate citric acid and magnesium oxide
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
Laxatives may increase the hypokalemic effect of dichlorphenamide
It may increase the hypokalemic effect when combined with laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
the activity of bisacodyl can be reduced when administered with agmatine
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
bismuth subcitrate, metronidazole and tetracycline
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
by inhibiting gastrointestinal absorption, the levels of potassium citrate may be decreased
bladderwrack may raise the laxative efficacy
Adverse drug reactions:  Â
Frequency Not DefinedÂ
Abdominal crampingÂ
NauseaÂ
Rectal burningÂ
VertigoÂ
Electrolyte and fluid imbalanceÂ
Excessive diarrheaÂ
VomitingÂ
Pregnancy warnings:    Â
US FDA pregnancy category: Not assigned.Â
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is unknownÂ
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this category
Patient Information Leaflet Â
Generic Name: bisacodyl Â
Pronounced: bis-AK-oh-dilÂ
Why do we use bisacodyl?Â
bisacodyl is a laxative drug which is used to treat constipationÂ